Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Males With Cystic Fibrosis Have Larger Central Airway Luminal Areas Than Females
Guyer, R.E., Miller, Andrew , Dominelli, Paolo B. , Sanz, Javier, Welch, Brian T. , Miller, Alex J. , Roden, Richard , Joyner, Michael J. , Ramsook, Andrew H , Baker, Sarah E.

Mayo Clinic

C74. CYSTIC FIBROSIS AND NON-CF BRONCHIECTASIS | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6465-A6465

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6465 Get It

Efficacy and Safety of Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis With Lung Involvement: A Post Hoc Analysis of the ADVOCATE Trial
Fussner, Lynn A. , Bray, Sarah , Gurlin, Rachel E , Group, ADVOCATE Study, Specks, Ulrich , Jayne, David , Merkel, Peter A.

Mayo Clinic

A26. IMPROVING OUTCOMES IN SARCOIDOSIS, RARE LUNG DISEASE AND LUNG TRANSPLANT | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1182-A1182

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1182 Get It

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
Wagemann, Olivia , Shi, Xinyu , Bittner, Tobias , Scelsi, Marzia A. , Farlow, Martin R. , Clifford, David B. , Santacruz, Anna , Aschenbrenner, Andrew J. , Hassenstab, Jason , Gordon, Brian A. , Coalier, Kelley A., Perrin, Richard J., Xiong, Chengjie , Li, Yan , Morris, John C. , Lah, James J., Berman, Sarah , Roberson, Erik D. , Dyck, Christopher H. van, Gauthier, Serge , Pariente, Jérémie , Mummery, Catherine J. , Day, Gregory S. , Ringman, John M. , Méndez, Patricio Chrem, Fox, Nick C. , Okhravi, Hamid , Chhatwal, Jasmeer P. , Xiong, Chengjie , Sims, John R. , Holdridge, Karen C. , Proctor, Nicholas K. , Yaari, R. , Andersen, Scott W. , Mancini, Michele , Unit, Dominantly Inherited Alzheimer Network–Trials, Daniels, Alisha , Courtney, Laura, Lu, Ruijin , Gremminger, Emily, Franklin, Erin , Jerome, Gina, Herries, Elizabeth, Baker, Bryce, Minton, Matthew, Goate, Alison , Picarello, Danielle M. , Hornbeck, Russ C. , Chen, Allison , Chen, Charles D., Jarman, Steve, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Sabaredzovic, Edita, Smith, Hunter , Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Nadkarni, Neelesh K. , Graff‐Radford, Neill R. , Huey, Edward D. , Salloway, Stephen , Bechara, Jacob , Ryan, Natalie S. , Laske, Christoph , Hofmann, Anna, Kuder-Buletta, Elke, Gräber‐Sultan, Susanne, Obermueller, Ulrike, Roedenbeck, Yvonne, Sánchez‐Valle, Raquel , Vázquez, Silvia , Leon, Yudy Milena, Ramírez, Laura, Seyfried, Nicholas T. , Fagan, Anne M. , Mori, Hiroshi , Gordon, Brian A , Roberson, Erik , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , Liu, Haiyan , Wang, Guoqiao , Supnet, Charlene , Benzinger, Tammie L.S. , Cruchaga, Carlos , Ibanez, Laura , Li, Yan, Dyck, Christopher H. van , Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Brooks, William S. , George‐Hyslop, Peter St , Suzuki, Kazushi , Jucker, Mathias , Mancini, Michele, Llibre‐Guerra, Jorge J. , Bateman, Randall J. , McDade, Eric , Unit, Dominantly Inherited Alzheimer Network–Trials, Xu, Xiong, Stauber, Jennifer, Renton, Alan , Flores, Shaney , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wáng, Qīng , Smith, Jennifer A. , Stout, Sarah Holtz , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Noble, James M. , Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Schofield, Peter R. , Martins, Ralph N. , Cash, David M. , Vöglein, Jonathan , Lee, Jae‐Hong , Roh, Jee Hoon , Rosa-Neto, Pedro , Allegri, Ricardo , Surace, Ezequiel , Lopera, Francisco Javier , Aguillon, David , Levey, Allan I. , Johnson, Erik C. B. , Masters, Colin L.

Mayo Clinic

JAMA Neurology | April 29, 2024 | Volume: 81 | Issue: 6 | Pages: 582

10.1001/jamaneurol.2024.0991 | PMID 38683602 Get It

Importance Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD). Objective To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment. Design, Setting, and Participants From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted from April to June 2023. DIAN-TU-001 spans 25 study sites in 7 countries. Biofluids and neuroimaging from carriers of DIAD gene variants in the gantenerumab, solanezumab, and placebo groups were analyzed. Interventions In 2016, initial dosing of gantenerumab, 225 mg (subcutaneously every 4 weeks) was increased every 8 weeks up to 1200 mg. In 2017, initial dosing of solanezumab, 400 mg (intravenously every 4 weeks) was increased up to 1600 mg every 4 weeks. Main Outcomes and Measures Longitudinal changes in CSF levels of neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3–like 1 protein (YKL-40), glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL), and plasma levels of GFAP and NfL. Results Of 236 eligible participants screened, 43 were excluded. A total of 142 participants (mean [SD] age, 44 [10] years; 72 female [51%]) were included in the study (gantenerumab, 52 [37%]; solanezumab, 50 [35%]; placebo, 40 [28%]). Relative to placebo, gantenerumab significantly reduced CSF neurogranin level at year 4 (mean [SD] β = −242.43 [48.04] pg/mL; P < .001); reduced plasma GFAP level at year 1 (mean [SD] β = −0.02 [0.01] ng/mL; P = .02), year 2 (mean [SD] β = −0.03 [0.01] ng/mL; P = .002), and year 4 (mean [SD] β = −0.06 [0.02] ng/mL; P < .001); and increased CSF sTREM2 level at year 2 (mean [SD] β = 1.12 [0.43] ng/mL; P = .01) and year 4 (mean [SD] β = 1.06 [0.52] ng/mL; P = .04). Solanezumab significantly increased CSF NfL (log) at year 4 (mean [SD] β = 0.14 [0.06]; P = .02). Correlation analysis for rates of change found stronger correlations between CSF markers and fluid markers with Pittsburgh compound B positron emission tomography for solanezumab and placebo. Conclusions and Relevance This randomized clinical trial supports the importance of fibrillar amyloid reduction in multiple AD-related processes of neuroinflammation and neurodegeneration in CSF and plasma in DIAD. Additional studies of antiaggregated amyloid therapies in sporadic AD and DIAD are needed to determine the utility of nonamyloid biomarkers in determining disease modification. Trial Registration ClinicalTrials.gov Identifier: NCT04623242
Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients
Aksamit, Timothy R. , Locantore, Nicholas , Ali, Juzar , Behrman, Megan, Brunton, Amanda E. , Chalmers, Sarah , Choate, Radmila , Dean, Nathan C. , DiMango, Angela, Fraulino, David , Johnson, Margaret M. , Lapinel, N. , McShane, Pamela J. , Miller, Bruce E. , Naureckas, Edward T. , O’Donnell, Anne E., Olivier, Kenneth N., Prusinowski, Elly, Richards, C. , Rhyne, Gloria, Thomashow, Byron, Tino, Gregory , Tsui, K., Varghese, Sumith Abraham, Warren, Heather E., Winthrop, Kevin , Zha, Beth Shoshanna, Addrizzo-Harris, Doreen , Basavaraj, Ashwin , Brunton, Amanda E , Chalmers, Sarah , Choate, Radmila , Dean, Nathan C , Johnson, Margaret M , Maselli, Diego J , McShane, Pamela J , Miller, Bruce E , O'Donnell, Anne E , Olivier, Kenneth N , Restrepo, Marcos I , Richards, Christopher J , Solomon, George M , Tal-Singer, Ruth , Zha, Beth Shoshanna , Addrizzo‐Harris, Doreen , BARKER, ALAN ROBERT , Metersky, Mark L. , Schmid, Andreas, Tal‐Singer, Ruth , Varghese, Sumith Abraham

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 26, 2024 | Volume: 210 | Issue: 1 | Pages: 108-118

10.1164/rccm.202307-1165oc | PMID 38668710 Get It

Abstract Rationale Nontuberculous mycobacteria (NTM) are prevalent among patients with bronchiectasis. However, the long-term natural history of patients with NTM and bronchiectasis is not well described. Objectives To assess the impact of NTM on 5-year clinical outcomes and mortality in patients with bronchiectasis. Methods Patients in the Bronchiectasis and NTM Research Registry with ⩾5 years of follow-up were eligible. Data were collected for all-cause mortality, lung function, exacerbations, hospitalizations, and disease severity. Outcomes were compared between patients with and without NTM at baseline. Mortality was assessed using Cox proportional hazards models and the log-rank test. Measurements and Main Results In total, 2,634 patients were included: 1,549 (58.8%) with and 1,085 (41.2%) without NTM at baseline. All-cause mortality (95% confidence interval) at Year 5 was 12.1% (10.5%, 13.7%) overall, 12.6% (10.5%, 14.8%) in patients with NTM, and 11.5% (9.0%, 13.9%) in patients without NTM. Independent predictors of 5-year mortality were baseline FEV1 percent predicted, age, hospitalization within 2 years before baseline, body mass index, and sex (all P < 0.01). The probabilities of acquiring NTM or Pseudomonas aeruginosa were approximately 4% and 3% per year, respectively. Spirometry, exacerbations, and hospitalizations were similar, regardless of NTM status, except that annual exacerbations were lower in patients with NTM (P < 0.05). Conclusions Outcomes, including exacerbations, hospitalizations, rate of loss of lung function, and mortality rate, were similar across 5 years in patients with bronchiectasis with or without NTM.
α‐Synuclein seed amplification assay detects Lewy body co‐pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden
Xiong, Chengjie , Quadalti, Corinne , Rossi, Marcello , Vöglein, Jonathan , Bernhardt, Alexander , Perrin, Richard J. , Preische, Oliver, Hofmann, Anna, Cairns, Nigel J. , Franklin, Erin , Chrem, Patricio, Berman, Sarah , Chhatwal, Jasmeer P. , Daniels, Alisha , Day, Gregory S. , Ryan, Natalie S. , Goate, Alison , Gordon, Brian A. , Huey, Edward D. , Masters, Colin L. , Morris, John C. , Noble, James M. , Roh, Jee Hoon , Frosch, Matthew P. , Sánchez‐Valle, Raquel , Supnet, Charlene , Network, Dominantly Inherited Alzheimer, Xiong, Chengjie , Parchi, Piero , Gordon, Brian A , Sánchez-Valle, Raquel , Day, Gregory S , Masters, Colin L , Vöglein, Jonathan , Morris, John C , Roh, Jee Hoon , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Noble, James M , Baiardi, Simone , Iranzo, Alex , Jucker, Mathias , Höglinger, Günter U. , Cruchaga, Carlos , Ibanez, Laura , Karch, Celeste M. , Lee, Jae‐Hong , Llibre‐Guerra, Jorge J. , Lopera, Francisco Javier , Renton, Alan , Keene, C. Dirk , McLean, Catriona , Schofield, Peter R. , Xiong, Chengjie , Giese, Armin , Hansson, Oskar , Bateman, Randall J. , McDade, Eric , Network, Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | April 26, 2024 | Volume: 20 | Issue: 6 | Pages: 4351-4365

10.1002/alz.13818 | PMID 38666355 Get It

AbstractINTRODUCTIONAmyloid beta and tau pathology are the hallmarks of sporadic Alzheimer's disease (AD) and autosomal dominant AD (ADAD). However, Lewy body pathology (LBP) is found in ≈ 50% of AD and ADAD brains.METHODSUsing an α‐synuclein seed amplification assay (SAA) in cerebrospinal fluid (CSF) from asymptomatic (n = 26) and symptomatic (n = 27) ADAD mutation carriers, including 12 with known neuropathology, we investigated the timing of occurrence and prevalence of SAA positive reactivity in ADAD in vivo.RESULTSNo asymptomatic participant and only 11% (3/27) of the symptomatic patients tested SAA positive. Neuropathology revealed LBP in 10/12 cases, primarily affecting the amygdala or the olfactory areas. In the latter group, only the individual with diffuse LBP reaching the neocortex showed α‐synuclein seeding activity in CSF in vivo.DISCUSSIONResults suggest that in ADAD LBP occurs later than AD pathology and often as amygdala‐ or olfactory‐predominant LBP, for which CSF α‐synuclein SAA has low sensitivity.Highlights Cerebrospinal fluid (CSF) real‐time quaking‐induced conversion (RT‐QuIC) detects misfolded α‐synuclein in ≈ 10% of symptomatic autosomal dominant Alzheimer's disease (ADAD) patients. CSF RT‐QuIC does not detect α‐synuclein seeding activity in asymptomatic mutation carriers. Lewy body pathology (LBP) in ADAD mainly occurs as olfactory only or amygdala‐predominant variants. LBP develops late in the disease course in ADAD. CSF α‐synuclein RT‐QuIC has low sensitivity for focal, low‐burden LBP.
Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities
Khera, Nandita , Brazauskas, Ruta , Patel, Jinalben , Üstün, Celalettin , Ballen, Karen K. , Abid, Muhammad Bilal , Díaz, Miguel Ángel , Al‐Homsi, A. Samer, Hong, Sanghee , Munker, Reinhold , Schears, Raquel M. , Ciurea, Stefan O. , Wirk, Baldeep , LeMaistre, Charles F. , Aljurf, Mahmoud , Sharma, Akshay , Černý, Jan , Kindwall‐Keller, Tamila L. , Winestone, Lena E. , Steinberg, Amir , Arnold, Staci D. , Seo, Sachiko , Preussler, Jaime M. , Hossain, Nasheed , Hashmi, Shahrukh K. , Lehmann, Leslie , Wood, William A. , Rangarajan, Hemalatha G. , Saber, Wael , Hahn, Theresa , Patel, Jinalben , Ustun, Celalettin , Abid, Muhammad Bilal , Diaz Perez, Miguel Angel , Hashem, Hasan , Ciurea, Stefan O , Badawy, Sherif M , Savani, Bipin N , LeMaistre, C Fred , Bhatt, Neel S , Sharma, Akshay , Cerny, Jan , Knight, Jennifer M , Kelkar, Amar H , Winestone, Lena E , Arnold, Staci D , Seo, Sachiko , Preussler, Jaime M , Hossain, Nasheed M , Fingrut, Warren B , Hashmi, Shahrukh K , Rangarajan, Hemalatha G , Wood, William A , Ailawadhi, Sikander , Jacobs, Benjamin, Hashem, Hasan , Lazarus, Hillard M. , Badawy, Sherif M. , Savani, Bipin N. , Bhatt, Neel S. , Beitinjaneh, Amer , Knight, Jennifer M. , Yared, Jean A. , Fingrut, Warren , Agrawal, Vaibhav

Mayo Clinic

Blood Advances | April 25, 2024 | Volume: 8 | Issue: 13 | Pages: 3497-3506

10.1182/bloodadvances.2023012469 | PMID 38661372 Get It

Abstract There has been an increase in volume as well as an improvement in overall survival (OS) after hematopoietic cell transplantation (HCT) for hematologic disorders. It is unknown if these changes have affected racial/ethnic minorities equally. In this observational study from the Center for International Blood and Marrow Transplant Research of 79 904 autologous (auto) and 65 662 allogeneic (allo) HCTs, we examined the volume and rates of change of autoHCT and alloHCT over time and trends in OS in 4 racial/ethnic groups: non-Hispanic Whites (NHWs), non-Hispanic African Americans (NHAAs), and Hispanics across 5 2-year cohorts from 2009 to 2018. Rates of change were compared using Poisson model. Adjusted and unadjusted Cox proportional hazards models examined trends in mortality in the 4 racial/ethnic groups over 5 study time periods. The rates of increase in volume were significantly higher for Hispanics and NHAAs vs NHW for both autoHCT and alloHCT. Adjusted overall mortality after autoHCT was comparable across all racial/ethnic groups. NHAA adults (hazard ratio [HR] 1.13; 95% confidence interval [CI] 1.04-1.22; P = .004) and pediatric patients (HR 1.62; 95% CI 1.3-2.03; P < .001) had a higher risk of mortality after alloHCT than NHWs. Improvement in OS over time was seen in all 4 groups after both autoHCT and alloHCT. Our study shows the rate of change for the use of autoHCT and alloHCT is higher in NHAAs and Hispanics than in NHWs. Survival after autoHCT and alloHCT improved over time; however, NHAAs have worse OS after alloHCT, which has persisted. Continued efforts are needed to mitigate disparities for patients requiring alloHCT.
Abstract 18573: Genetic Variation of the Alpha-Subunit of the Epithelial Sodium Channel Influences the Lung Fluid Response to Hypoxia in Healthy Humans
Wheatley, Courtney M. , Johnson, Bruce , Snyder, Eric M. , Baker, Sarah E. , Taylor, Bryan J. , Keller‐Ross, Manda L. , Johnson, Bruce, Snyder, Eric M

Mayo Clinic

Circulation | April 23, 2024 | Volume: 128 | Issue: suppl_22 | Pages: No page available

10.1161/circ.128.suppl_22.a18573 Get It

Cardiogenic pulmonary edema is a life-threatening complication in patients with heart failure (HF) resulting from increased alveolar Cl- secretion and inhibition of alveolar epithelial Na+ channels (ENaC). Not all HF patients develop pulmonary edema, despite similar clinical characteristics, suggesting a genetic component to edema formation in response to cardiac failure. The ENaC are crucial for alveolar fluid clearance, with the alpha subunit demonstrating particular importance. We have previously found that genetic variation of the alpha subunit (SCNN1A) of ENaC, an alanine (A) to threonine (T) substitution, influences ion regulation during exercise and in response to albuterol. In the present study, we sought to determine the influence of the threonine variant (T663; AT/TT group) on lung fluid regulation in response to normobaric hypoxia, an environmental condition known to increase pulmonary capillary hydrostatic stress in healthy humans. Lung ion and fluid changes were assessed using exhaled Na+ (ENa+) and the lung diffusing capacity for carbon monoxide and nitric oxide (DLCO and DLNO, respectively) to determine alveolar-capillary membrane conductance (DM). 19 healthy subjects (n=8 vs. 11, %female=50 vs. 62%, age=27±1 vs. 28±2yrs., ht=171±3 vs. 173±2cm, wt=69±6 vs.72±3kg , BMI=23±1 vs.24±1kg/m2 , for AA and AT/TT, respectively) completed two overnight visits in a hypoxic tent simulating just over 5,400m. The visits were randomized to inhaled placebo (P) or inhaled amiloride (Aml, 1.5mg in 5ml normal saline, used to inhibit ENaC activity) with ENa+, DLCO, and DM assessed at baseline and following 12 hours of hypoxic exposure. There was an effect of genotype on the ENa+ response to hypoxia with placebo that was abolished with amiloride, but no effect of genotype on the diffusing capacity of the lung (Table). These results suggest that genetic variation of SCNN1A may influence ion regulation in the lung under conditions of elevated hydrostatic stress.
Buprenorphine affects the initiation and severity of interleukin-induced acute pancreatitis in mice
Jahangir, Sarah , Smichi, Nabil , Rajalingamgari, Prasad , Pillai, Anoop Narayana, Summers, Megan J., McFayden, Bryce , Gades, Naomi M. , Singh, Vijay , Khatua, Biswajit , Rajalingamgari, Prasad , Narayana Pillai, Anoop, Singh, Vijay P , Summers, Megan E., Kostenko, Sergiy

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | April 23, 2024 | Volume: 327 | Issue: 1 | Pages: G16-G24

10.1152/ajpgi.00083.2024 | PMID 38651230 Get It

Extended-release buprenorphine interferes with the initiation and progression of acute pancreatitis at multiple levels.
0632 Design Elements for a Switch Study from High- to Low-Sodium Oxybate Evaluating Blood Pressure in Narcolepsy (XYLO)
White, William B. , Macfadden, Wayne , Baranak, Christine, Nichols, Deborah A. , Akerman, Sarah , Somers, Virend K.

Mayo Clinic

SLEEP | April 20, 2024 | Volume: 47 | Issue: Supplement_1 | Pages: A270-A270

10.1093/sleep/zsae067.0632 Get It

Abstract Introduction High sodium intake can increase blood pressure (BP) and future cardiovascular risk. Individuals with narcolepsy have an elevated cardiovascular comorbidity burden before considering medication-specific risks. Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration (FDA) to treat excessive daytime sleepiness or cataplexy in patients ≥7 years of age with narcolepsy and idiopathic hypersomnia in adults. LXB has the same active moiety as high-sodium oxybates (sodium oxybate [SXB, Xyrem®] and fixed-dose SXB [Lumryz™]) but contains 92% less sodium. The objective of XYLO is to measure ambulatory and in-clinic systolic BP (SBP) changes after switching to LXB from a high-sodium oxybate in participants with narcolepsy (NCT05869773). Methods This 6-week, open-label, multicenter, switch study is enrolling participants 18–70 years of age with narcolepsy (type 1 or 2) taking 6–9 g/night of high-sodium oxybate for ≥6 weeks. Hybrid enrollment supports both on-site and decentralized (monitored at the participant’s home by mobile health professionals) participation, and may broaden the pool of eligible participants. After ≥2 weeks on stable high-sodium oxybate dose/regimens (screening period), participants switch to the same dose/regimen of LXB for 6 weeks (intervention period). The primary endpoint is the change in 24-hour SBP from baseline (the most recent screening measurement prior to switching) to the end-of-treatment visit (approximately 6 weeks after switching) measured via 24-hour ambulatory BP monitoring (ABPM). Secondary endpoints evaluate change from baseline to end-of-treatment visit in-clinic SBP, as well as daytime average SBP and nighttime average SBP measured via 24-hour ABPM. Results Recruitment began in June 2023. This study uses a group sequential design with an adaptive sample size target of 57–77 participants completing the 6-week intervention period. This design provides 90% power to detect a mean difference of 3.5 mmHg (a clinically relevant change) in 24-hour SBP (assuming a standard deviation of the differences in 24-hour SBP of 8 mmHg). Conclusion XYLO will enable the assessment of 24-hour BP changes following transition from a high-sodium oxybate to LXB. Planned hybrid enrollment with a decentralized option may increase study access leading to a more diverse clinical trial population. Support (if any) Jazz Pharmaceuticals
The Effect of C2 Muscular Exposure Technique on Radiographic and Clinical Outcomes After C2–T2 Posterior Cervical Fusion
Pumford, Andrew, Townsley, Sarah, Reed, Ryder, Chen, Selby , Deen, H. Gordon , Bydon, Mohamad , Fogelson, Jeremy L. , Elder, Benjamin D. , Currier, Bradford L. , Freedman, Brett A. , Sebastian, Arjun S. , Katsos, Konstantinos, Clarke, Michelle, Levy, Hannah A. , Pinter, Zachariah W. , Salmons, Harold I. , Katsos, Konstantinos, Abode-Iyamah, Kingsley , Clarke, Michelle J. , Nassr, Ahmad , Karamian, Brian A.

Mayo Clinic

Clinical Spine Surgery | April 19, 2024 | Volume: 37 | Issue: 10 | Pages: E448-E454

10.1097/bsd.0000000000001626 | PMID 38637921 Get It

Study Design: Retrospective cohort analysis. Objective: To determine whether the C2 exposure technique was a predictor of change in cervical alignment and patient-reported outcomes measures (PROMs) after posterior cervical decompression and fusion (PCDF) for degenerative indications. Background: In PCDF handling of the C2 posterior paraspinal musculature during the operative approach varies by surgeon technique. To date, no studies have investigated whether maintenance of the upper cervical semispinalis cervicis attachments as compared with complete reflection of upper cervical paraspinal musculature from the posterior bony elements is associated with superior radiographic and clinical outcomes after PCDF. Patients and Methods: All adult patients who underwent C2–T2 PCDF for myelopathy or myeloradiculopathy at multi-institutional academic centers between 2013 and 2020 were retrospectively identified. Patients were dichotomized by the C2 exposure technique into semispinalis preservation or midline muscular reflection groups. Preoperative and short and long-term postoperative radiographic outcomes (upper cervical alignment, global alignment, and fusion status) and PROMs (Visual Analog Scale–Neck, Neck Disability Index, and Short Form-12) were collected. Univariate analysis compared patient factors, radiographic measures, and PROMs across C2 exposure groups. Results: A total of 129 patients met the inclusion/exclusion criteria (73 muscle preservation and 56 muscle reflection). Patients in the muscular preservation group were on average younger (P = 0.005) and more likely to have bone morphogenic protein (P < 0.001) and C2 pars screws (P = 0.006) used during surgery. Preoperative to postoperative changes in C2 slope, C2 tilt, C2–C3 segmental lordosis, C2–C3 listhesis, C0–C2 Cobb angle, proximal junctional kyphosis, ADI, C1 lamina-occiput distance, C2 sagittal vertical axis, C2–C7 lordosis, and PROMs at all follow-up intervals did not vary significantly by C2 exposure technique. Likewise, there were no significant differences in fusion status, C2–C3 pseudoarthrosis, C2 screw loosening, and complication and revision rates between C2 exposure groups. Conclusions: Preservation of C2 semispinalis attachments versus muscular reflection did not significantly impact cervical alignment, clinical outcomes, or proximal junction complications in long-segment PCDF. Level of Evidence: Level III.